Bank of America’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Bank of America’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-541,875	Closed	-$12.5M	–	8069
2020 Q4	$12.5M	Buy	541,875 +59,074	+12%	+$749K	﹤0.01%	2297
2020 Q3	$4.92M	Buy	482,801 +227,246	+89%	+$3.05M	﹤0.01%	2925
2020 Q2	$3.81M	Sell	255,555 -3,194	-1%	-$49.2K	﹤0.01%	3086
2020 Q1	$3.15M	Sell	258,749 -18,532	-7%	-$295K	﹤0.01%	3111
2019 Q4	$4.39M	Buy	277,281 +36,821	+15%	+$470K	﹤0.01%	3360
2019 Q3	$2.95M	Buy	240,460 +240,260	+120,130%	+$2.72M	﹤0.01%	3696
2019 Q2	$3K	Buy	+200	New	+$2.92K	﹤0.01%	6928

Bank of America's PRVL Position: Q1 2021 in Review

Bank of America sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 541,875 shares — an estimated $12.5M sold.

Bank of America first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $12.5M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Bank of America reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Bank of America sold 541,875 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $12.5M.
Bank of America first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
Bank of America's Prevail Therapeutics Inc. Common Stock position peaked at $12.5M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Bank of America's 13F filing for Q1 2021, filed 14 May 2021.